


| European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia |
|
BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.) The company remains on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2020. Vosoritide has Orphan Drug designation from the FDA and the EMA.
Posted: 2020-08-13 14:44:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.